#151170

Anti-HPV16E7 [TVG 701Y] mAb

Please Enter Your Email ID
Email ID

Cat. #151170

Anti-HPV16E7 [TVG 701Y] mAb

Cat. #: 151170

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-5 days

Target: Human Papilloma Virus-16 early protein 7 (HPV16 E7)

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; IF ; WB

Reactivity: Human papilloma virus

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Cambridge

Primary Citation: Tommasino et al. 1993. Oncogene. 8(1):195-202. PMID: 8380917.

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-HPV16E7 [TVG 701Y] mAb
  • Alternate name: Anti-Human Papillomavirus 16 (E7) antibody [TVG 701Y]; Anti-HPV16E7 [TVG 701Y]; HPV16 E7; Protein E7; E7; HPV antibody
  • Cancer: Gynaecologic cancer
  • Cancers detailed: Cervical
  • Research fields: Cancer;Microbiology
  • Clone: TVG 701Y
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Purpose: Marker
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human papilloma virus
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; IF ; WB
  • Description: Tumour antigens are proteins found in tumour cells and recognised by cellular or humoral effectors of the immune system. Tumour antigens are useful in identifying cancer cells, they also can be leveraged as targets in cancer therapy. Anti-Human Papillomavirus 16 (E7) antibody [TVG 701Y] also known as Anti-HPV16E7 [TVG 701Y] is an antibody against a tumour-specific antigen (TSA). TSA's are restricted to tumours and are not found in healthy cells. Anti-HPV16E7 [TVG 701Y] is a monoclonal antibody against HPV16E7. The human papilloma virus (HPV) family of DNA tumour viruses includes HPV-16 and HPV-18. These are associated with a large proportion of cervical cancer cases. E7 is the major transforming protein of human papillomavirus type 16 (HPV16). The immunogen is HPV 16 E7 synthesised from S. pombe.
  • Immunogen: HPV 16 E7 synthesised from S. pombe
  • Isotype: IgG2a
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Human Papilloma Virus-16 early protein 7 (HPV16 E7)
  • Tissue cell line specificity: Mouse
  • Target background: The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer cases. HPV early proteins E6 and E7 are the major viral oncoproteins that regulate cell proliferation through the inactivation of p53 and Rb1 tumour suppressor proteins respectively.

Applications

  • Application: ELISA ; FACS ; IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Chen et al. 2020. Antiviral Res. 178:104794. PMID: 32298665.
  • Kannan et al. 2017. Sci Rep. 7:46102. PMID: 28383029.
  • Harris et al. 2013. Br J Cancer. 108(4):859-865. PMID: 23385729.
  • Tommasino et al. 1993. Oncogene. 8(1):195-202. PMID: 8380917.